bioihbjkbjnl/mcl2 huggingface dataset:
Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane
Condition: Anesthesia, General
Study type: Observational

Summary: 
      This registry is primarily aiming to demonstrate the correlation between good practices of
      anesthesiologists and patient related outcomes including decreased overall anesthesia cost.
      The investigators would also like to demonstrate how the training background, and experience
      in inhalational anesthesia of the anesthesiologist influence their daily practice. At the end
      of the registry, the investigators would be able to demonstrate the influence of different
      practice pattern on patient related outcomes between the sites at which anesthesiologists
      follow modern anesthesiology practice based on their training/experience background and at
      which anesthesiologists do not follow same type of practice due to lack of their inhalational
      anesthesia training/experience.
    


Observational model: Case-Only
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Chinese patients undergoing surgery requiring general anesthesia with endotracheal
        intubation or laryngeal mask airway
      
Keywords: Sevoflurane; Physician's Practice Patterns; Economics, Pharmaceutical; Chinese
Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function
Condition: Epilepsy
MeSH terms: Epilepsy
Study type: Interventional
Phase: Phase 1

Summary: 
      Single-blind, single-centre, fixed-order study to evaluate the PD effects of a single oral
      dose and multiple oral doses of ESL (BIA 2-093) in healthy volunteers.
    

Detailed description: 
      Single-blind, single-centre, fixed-order study to evaluate the PD effects of a single oral
      dose and multiple oral doses of ESL (BIA 2-093) in healthy volunteers. A single dose of oral
      ESL 900 mg was followed by consecutive 7-day periods of: Placebo, ESL 800 mg, and ESL 1200 mg
      each given QD. The single dose was chosen to assess the ESL acute response relationship with
      respect to cognitive and motor skill performance, and the multiple doses were chosen to
      further characterize the ESL dose response relationship with respect to cognitive and motor
      skill performance.
    

Intervention name(s): BIA 2-093
Intervention type(s): Drug
Other intervention name(s): ESL, Eslicarbazepine acetate
Intervention MeSH terms: Eslicarbazepine acetate
Intervention model: Single Group Assignment
Masking: Single (Participant)
Primary purpose: Treatment
Leveraging mHealth Messaging to Promote Adherence in Teens With CKD
Condition: Chronic Kidney Diseases; Adherence, Medication; Communication
MeSH terms: Kidney Diseases; Renal Insufficiency, Chronic
Study type: Interventional

Summary: 
      The overall goal of this study is to develop and test effectively framed mobile health
      (mHealth) messages to promote medication adherence in teens with chronic kidney disease
      (CKD).
    

Detailed description: 
      Hypertension is a risk factor for chronic kidney disease (CKD) progression. Only 77% of
      adolescents with CKD are adherent to antihypertensive medications despite evidence that
      adherence slows disease progression. Mobile health (mHealth) applications show promise for
      improving adherence but most are not designed within health-promotion frameworks, only send
      medication reminders, use unreliable outcome measures, and/or have small effects on
      adherence. Nonadherence is a public health problem that may benefit from using health
      communication strategies to advance beyond reminders and improve mHealth efficacy. Highly
      effective health messages modify perceptions, attitudes, and skills to facilitate behavioral
      change; inappropriately framed messages (e.g., use of fear appeals) may have unintended,
      negative effects on health behaviors (i.e., reduce adherence). For adolescents with CKD,
      framing mHealth messages to motivate adherence may be a key factor in preventing disease
      progression; however, there has been little research to guide the use of this approach.
      Hence, the current study aims to develop and test effectively framed mobile health (mHealth)
      messages to promote medication adherence in teens with CKD.

      Prior to study recruitment, the intervention messages will be developed by the research team
      and key stakeholders before testing in this pilot randomized controlled trial (RCT).
      Adolescents/young adults with CKD will be invited to participate in the pilot RCT to evaluate
      the intervention messages versus an active control condition; the primary outcome is
      antihypertensive medication adherence and secondary outcomes are participants' responses to
      surveys.
    

Intervention name(s): mHealth Messaging Intervention Group; Standard mHealth Messaging Group
Intervention type(s): Behavioral; Behavioral
Intervention description(s): The newly developed intervention messages will be sent to individuals assigned to the intervention group during the study.; Standard mHealth messages will be sent to individuals assigned to the active control group during the study.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Treatment
Keywords: Adherence; Adolescence; mHealth
Irritable Bowel Syndrome and Lactibiane Tolerance
Condition: Irritable Bowel Syndrome
MeSH terms: Irritable Bowel Syndrome; Syndrome
Study type: Interventional

Summary: 
      The purpose of this study is to evaluate the effects of a probiotic combination (Lactibiane
      Tolerance) on the severity of symptoms in patients with irritable bowel syndrome (IBS).
    

Detailed description: 
      The primary purpose of this study is to evaluate the effects of a probiotic combination
      (Lactibiane Tolerance) on the severity of symptoms in patients with irritable bowel syndrome
      (IBS).

      The secondary purposes are to evaluate the effects of the intervention on:

        -  quality of life

        -  severity of fatigue, anxiety and depression

        -  levels of inflammatory markers in blood and tools
    

Intervention name(s): Lactibiane Tolerance; Placebo
Intervention type(s): Dietary Supplement; Dietary Supplement
Intervention description(s): Probiotics combination 2 gelules per days during 6 weeks; Placebo 2 gelules per days for 6 weeks
Other intervention name(s): Probiotic
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Irritable Bowel Syndrome; Probiotics
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
MeSH terms: Lupus Erythematosus, Systemic
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      International trial to evaluate the biological activity and safety of cenerimod (ACT-334441)
      in systemic lupus erythematosus (SLE) patients.
    

Detailed description: 
      This multicentre, double-blind, placebo-controlled study will have a staggered approach (Part
      A and B).

      In part A, eligible patients will be randomly assigned (1:1:1:1) to once daily oral
      administration of cenerimod (0.5, 1, 2 mg) or placebo. After all patients have completed 4
      weeks of treatment during part A, an Independent Data Monitoring Committee will review
      non-blinded data in an interim analysis to evaluate the safety profile of cenerimod and
      recommend whether the study could proceed to part B.

      In part B, additional patients will be randomized (3:1) to once daily oral administration of
      cenerimod 4 mg or placebo.

      All participants will receive study medication for 12 weeks.
    

Intervention name(s): Matching placebo; Cenerimod
Intervention type(s): Drug; Drug
Intervention description(s): One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).; One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
Other intervention name(s): Placebo; ACT-334441
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Systemic lupus erythematosus
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
Condition: Head and Neck Cancer
MeSH terms: Salivary Gland Neoplasms
Study type: Interventional
Phase: Phase 2

Summary: 
      RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes
      necessary for tumor cell growth.

      PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients
      who have unresectable and/or metastatic salivary gland cancer.
    

Detailed description: 
      OBJECTIVES:

        -  Determine the antitumor activity of imatinib mesylate, in terms of objective response
           rates (partial and complete responses) and duration of overall response, in patients
           with unresectable and/or metastatic adenoid cystic, lymphoepithelioma-like, or
           myoepithelial salivary gland cancer.

        -  Determine the safety and tolerability of this drug in these patients.

        -  Correlate the activity of c-kit and downstream kinases in pre- and post-treatment
           tumoral biopsies with clinical course in patients treated with this drug.

        -  Determine the effect of treatment with this drug on tumor samples from these patients in
           terms of proliferation, apoptosis, and angiogenesis.

        -  Correlate the steady state levels of this drug achieved with clinical and laboratory
           correlative endpoints in these patients.

        -  Determine whether early changes in metabolic activity correlate with molecular changes
           and predict outcome to therapy in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive oral imatinib mesylate twice daily. Courses repeat every 28 days in the
      absence of disease progression or unacceptable toxicity. Patients with stable disease receive
      treatment for up to 6 months.

      Patients are followed within 3 weeks and then every 3 months thereafter.

      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-19
      months.
    

Intervention name(s): imatinib mesylate
Intervention type(s): Drug
Intervention MeSH terms: Imatinib Mesylate
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: recurrent salivary gland cancer; salivary gland adenoid cystic carcinoma; stage III salivary gland cancer; stage IV salivary gland cancer
Apixaban in Subjects With Peritoneal Dialysis
Condition: Chronic Renal Insufficiency; Peritoneal Dialysis
MeSH terms: Renal Insufficiency; Renal Insufficiency, Chronic
Study type: Interventional
Phase: Phase 1

Summary: 
      The primary objective of this study is to assess the pharmacokinetics of a single oral dose
      of apixaban (5mg) in participants with dialysis peritoneal versus participants with normal
      renal function.
    

Detailed description: 
      Participants with chronic renal disease treated with peritoneal dialysis and participants
      with normal renal function are hospitalized for three days.
    

Intervention name(s): Apixaban Oral
Intervention type(s): Drug
Intervention description(s): one Tablet 5mg
Intervention MeSH terms: Apixaban
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Intervention model description: Two groups of participants will receive one single-dose of 5 mg of apixaban: the first group of participants with a normal renal function, the second group contains participants with end-stage renal disease treated with peritoneal dialysis.
Masking: None (Open Label)
Primary purpose: Other
Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study
Condition: Bipolar Disorder; Mania; Bipolar Depression
MeSH terms: Depression; Bipolar Disorder
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to determine whether the amino acid taurine has effects on mood
      stability in bipolar disorder.
    

Detailed description: 
      Taurine is an amino acid that has some actions similar to mood stabilizers. Taurine is widely
      sold as a component of over-the-counter mood enhancing agents. However, controlled studies
      examining the mood effects of taurine are limited. An initial study in this laboratory looked
      at taurine's mood effects in individuals with bipolar disorder. This follow-up study is
      designed to further examine taurine's effects on manic symptoms. Subjects in the current
      follow-up study will add taurine or placebo to their current treatment regimen. Both
      depressive and manic symptoms will be tracked for three months to determine whether the
      addition of taurine affects mood symptoms.
    

Intervention name(s): taurine
Intervention type(s): Drug
Intervention description(s): taurine 2mg BID po
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: bipolar; mania; depression; taurine; alternative
Clinical and Laboratory Evaluation of 3 Contact Lenses With 4 Contact Lens Solutions
Condition: Contact Lens Solutions
Study type: Interventional

Summary: 
      The purpose of this study is to evaluate the clinical and laboratory performance of three
      brand name contact lenses with three recently introduced multipurpose lens care solutions
      (test solutions) as well as a peroxide disinfecting solution (control solution).
    


Intervention name(s): Solution 1 (Test); Solution 2 (Test); Solution 3 (Test); Solution 4 (Control)
Intervention type(s): Other; Other; Other; Other
Intervention description(s): Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order; Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order; Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order; Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
Other intervention name(s): Revitalens; Pure Moist; Biotrue; Clear Care
Intervention MeSH terms: Pharmaceutical Solutions
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Supportive Care
Comparison of Two Different Resuscitation Devices
Condition: Manual Ventilation
Study type: Interventional

Summary: 
      There is a complex physiological process involved in establishing regular breaths at birth.
      After initiation of the first breath, fluid is removed from the alveoli and enough pressure
      must be generated to inflate the lungs . Most newborns will establish spontaneous regular
      breathing sufficient to maintain the heart rate above 100 beats/min and to improve perfusion
      within 3 minutes of birth. According to the neonatal resuscitation programme (NRP), if heart
      rate is below 100 or there is persistence of apnoea or gasping after the initial steps of
      drying/stimulation and oropharyngeal suction, intervention is required .

      The main focus of neonatal resuscitation is effective ventilation to improve gas exchange and
      prevent respiratory failure. After birth, approximately 4% to 10% of term and late preterm
      newborns will receive help breathing with positive-pressure ventilation (PPV). Adequate mask
      ventilation is essential when providing breaths during neonatal resuscitation. However, this
      can be difficult, especially for less experienced staff and may be affected by inadequate
      seal of the mask, gas leaks and airway obstruction. In addition, trauma may be caused by the
      volumes being given during pressure controlled ventilation.
    

Detailed description: 
      Comparison of two different neonatal resuscitation devices (Neopuff and rPAP) in the Neonatal
      Unit in Cork University Maternity Hospital. Participants will use the devices on a mannequin.
      Performance of the two devices is judged by comparing the tidal volumes produced.

      Participants will be recruited from the medical staff (Non-consultant Hospital Doctors and
      Consultants) of the neonatal unit.
    

Intervention name(s): Neopff; rPap
Intervention type(s): Device; Device
Intervention description(s): manual ventilation; Manual ventilation
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy
Condition: Colorectal Cancer; Liver Metastases
MeSH terms: Neoplasm Metastasis; Liver Neoplasms
Study type: Interventional
Phase: Phase 2

Summary: 
      The purpose of this study is to assess the predictive value of 99mTechnetium (Tc)- labeled
      albumin in macroaggregates (MAA) and in microspheres (B20) injected into the common hepatic
      artery for the distribution of 90Yttrium- Selective Internal Radiotherapy (SIRT)-spheres
      (SIR- spheres).
    

Detailed description: 
      Patients with metastases of colorectal tumors will be included into this study provided that
      they are scheduled for 90Y SIR spheres therapy for clinical reasons. Before 90Y SIR spheres
      therapy, patients will receive a diagnostic examination with injection of MAA (group A) or
      B20 (group B) into the common hepatic artery to rule out a relevant shunt volume to the lung
      or other extra-hepatic locations (e.g., stomach) as recommended by the manufacturer. After
      the diagnostic scan, therapy with SIR- spheres will be conducted in 2 separate sessions with
      selective injection of 90Y labeled SIR spheres into the right and left hepatic artery at two
      separate occasions (routine procedure at the University of Magdeburg, Germany). In addition,
      therapeutic sessions will include the selective injection of MAA or B20 into the right / left
      hepatic artery according to a predefined plan (either alone or as a mixture with the SIR
      spheres).The intra-hepatic distribution of 90Y labeled SIR spheres will be assessed using
      "Bremsstrahlen"- Single- Photon- Emission- Computed- Tomography (SPECT)- imaging, the
      distribution of MAA and B20 will be assessed using SPECT imaging.
    

Intervention name(s): MAA for diagnostic SPECT imaging; Diagnostic B20- SPECT imaging.
Intervention type(s): Drug; Drug
Intervention description(s): Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.; Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
Other intervention name(s): TechneScan Lyo MAA; ROTOP HSA microspheres B20
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Primary purpose: Diagnostic
Keywords: liver metastases; MAA; B20; SIR spheres; SPECT; intra-hepatic distribution
Enhanced Recovery Open Versus Laparoscopic Donor Nephrectomy
Condition: Renal Transplant Donor of Left Kidney
Study type: Interventional
Phase: Phase 3

Summary: 
      A phase III randomized trial conducted to compare recovery outcomes between laparoscopic and
      open donor nephrectomy within a specified enhanced recovery protocol
    

Detailed description: 
      The MEnROL trial is a phase III randomized controlled trial of Open versus Laparoscopic donor
      nephrectomy within a standardized enhanced recovery program. Eligible donors were randomized
      in a 1:1 ratio.

      Laparoscopic procedures are performed by a single surgeon (AMM) while Open donor
      nephrectomies (ODN) were performed by an experienced team that included the laparoscopic
      surgeon. ODN were performed via a supracostal incision above the 11th rib and an
      extra-pleural extra-peritoneal approach was adopted. Laparoscopic donor nephrectomy (LDN) was
      performed via a standard 4-port distribution. Control of the hilar vessels was performed
      using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft
      extraction was performed via a pre-prepared Pfannenstiel incision.

      Donors are enrolled in our enhanced recovery program for donor nephrectomy. The program was
      compliant with the Enhanced Recovery After Surgery Group (ERAS) guidelines. All donors
      receive epidural analgesia and are maintained on non-narcotic postoperative analgesics.
      Criteria for hospital discharge include ambulation, adequate pain control with oral
      analgesics, and sustained intake of solid food.
    

Intervention name(s): Laparoscopic donor nephrectomy; Open donor nephrectomy
Intervention type(s): Procedure; Procedure
Intervention description(s): Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision; Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Interaction Between ABT-335, Rosuvastatin and Warfarin
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      This is a multiple-dose, double-blind, randomized, single-center, parallel-group study in
      adult male subjects in general good health.
    


Intervention name(s): Warfarin; warfarin plus ABT-335 plus rosuvastatin 5 mg; warfarin plus ABT-335 plus rosuvastatin 20 mg
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.; Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.; Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
Other intervention name(s): Coumadin; warfarin; coumadin ABT-335; fenofibric acid; Trilipix Rosuvastatin; Crestor; warfarin; coumadin; ABT-335; fenofibric acid; Trilipix Rosuvastatin; Crestor
Intervention MeSH terms: Warfarin; Rosuvastatin Calcium; Fenofibric acid; Fenofibrate
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: Drug Interaction; Pharmacokinetics; Pharmacodynamics